Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2644-2647

  Zask, Arie ^a   Verheijen, Jeroen C ^a   Richard, David J ^a   Kaplan, Joshua ^a   Curran, Kevin ^a   Toral Barza, Lourdes ^a   Lucas, Judy ^a   Hollander, Irwin ^a   Yu, Ker ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Antiproliferative; Cancer; Inhibitor; Kinase; mTOR; Oncology; PI3K

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MORPHOLINE DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; DRUG DISCOVERY; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; MORPHOLINES; PROTEIN-SERINE-THREONINE KINASES; TRIAZINES;

MUS MUSCULUS;

EID: 77950055909     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.045     Document Type: Article

References (23)

1. Guertin D.A., and Sabatini D.M. Cancer Cell 12 (2007) 9
2. Chiang G.G., and Abraham R.T. Trends Mol. Med. 13 (2007) 433
3. Yuan T.L., and Cantley L.C. Oncogene 27 (2008) 5497
4. Verheijen J., Yu K., and Zask A. Annu. Rep. Med. Chem. 43 (2008) 189
5. Maira S.-M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., and Garcia-Echeverria C. Mol. Cancer Ther. 7 (2008) 1851
6. Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., Friedman L.S., Hayes A., Hancox T.C., Kugendradas A., Lensun L., Moore P., Olivero A.G., Pang J., Patel S., Pergl-Wilson G.H., Raynaud F.I., Robson A., Saghir N., Salphati L., Sohal S., Ultsch M.H., Valenti M., Wallweber H.J.A., Wan N.C., Wiesmann C., Workman P., Zhyvoloup A., Zvelebil M.J., and Shuttleworth S.J. J. Med. Chem. 51 (2008) 5522
7. Zask A., Verheijen J.C., Curran K., Kaplan J., Richard D.J., Nowak P., Malwitz D.J., Brooijmans N., Bard J., Svenson K., Lucas J., Toral-Barza L., Zhang W.-G., Hollander I., Gibbons J.J., Abraham R.T., Ayral-Kaloustian S., Mansour T.S., and Yu K. J. Med. Chem. 52 (2009) 5013
8. Verheijen J., Richard D., Curran K., Kaplan J., Lefever M., Nowak P., Malwitz D., Brooijmans N., Toral-Barza L., Zhang W.-G., Lucas J., Hollander I., Ayral-Kaloustian S., Mansour T., Yu K., and Zask A. J. Med. Chem. 52 (2009) 8010
9. Yu K., Toral-Barza L., Shi C., Zhang W.-G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., and Zask A. Cancer Res. 69 (2009) 6232
10. Zask A., Kaplan J., Verheijen J.C., Richard D.J., Curran K., Brooijmans N., Bennett E.M., Toral-Barza L., Hollander I., Ayral-Kaloustian S., and Yu Y. J. Med. Chem. 52 (2009) 7942
11. Richard D.J., Verheijen J.C., Curran K., Kaplan J., Brooijmans N., Toral-Barza L., Hollander I., Ayral-Kaloustian S., Yu K., and Zask A. Bioorg. Med. Chem. Lett. 19 (2009) 6830
12. Kaplan J., Verheijen J.C., Brooijmans N., Toral-Barza L., Hollander I., Yu K., and Zask A. Bioorg. Med. Chem. Lett. 20 (2010) 640
13. Verheijen J.C., Yu K., Toral-Barza L., Hollander I., and Zask A. Bioorg. Med. Chem. Lett. 20 (2010) 355
14. Feldman, M. E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z. A.; Ruggero, D.; Shokat, K. M. PLoS Biol. 2009, 7, e1000038, doi:10.1371/journal.pbio.1000038.
15. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., and Gray N.S. J. Biol. Chem. 284 (2009) 8023
16. García-Martínez J.M., Moran J., Clarke R.G., Gray A., Cosulich S.C., Chresta C.M., and Alessi D.R. Biochem. J. 421 (2009) 29
17. Malagu K., Duggan H., Menear K., Hummersone M., Gomez S., Bailey C., Edwards P., Drzewiecke J., Leroux F., Quesada M.J., Hermann G., Maine S., Molyneaux C.-A., Le Gall A., Pullen J., Hickson I., Smith L., Maguire S., Martin N., Smith G., and Pass M. Bioorg. Med. Chem. Lett. 19 (2009) 5950
18. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., James D., Howard Z., Dudley P., Hughes G., Smith L., Maguire S., Hummersone M., Malagu K., Menear K., Jenkins R., Jacobsen M., Smith G.C.M., Guichard S., and Pass M. Cancer Res. 70 (2010) 288
19. Phe961 in PI3K corresponds to Leu in mTOR. PI3Kγ amino acid sequence numbering is used.
20. Verheijen J.C., Richard D.J., Curran K., Kaplan J., Yu K., and Zask A. Bioorg. Med. Chem. Lett. 20 (2010) 2648
21. Richard D.J., Verheijen J.C., Yu K., and Zask A. Bioorg. Med. Chem. Lett. 20 (2010) 2654
22. Kong D., and Yamori T. Cancer Sci. 98 (2007) 1638
23. Biological methods for determination of inhibition of cellular proliferation are described in Yu, K.; Toral-Barza, L.; Discafani, C.; Zhang, W. G.; Skotnicki, J.; Frost, P.; Gibbons, J. Endocrinol. Relat. Cancer 2001, 8, 249.